ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
News Sep 19, 2008
ThermoGenesis Corp. has signed a distribution agreement with Celling Technologies for ThermoGenesis' MarrowXpress (MXP™) product line used for isolating stem cells from bone marrow. The distribution rights are for the field of use in orthopedic intraoperative or point-of-care applications.
Celling Technologies will begin using the MXP to perform bone marrow stem cell separation for its existing point-of-care orthopedic procedures and perform clinical research utilizing this technology.
The MXP offers a computerized control in the separation of stem cells from bone marrow aspirate which is first to market technology allowing surgeons to automate the steps with consistent cell separation accuracy and cryopreservation capabilities. In the field of regenerative medicine, a high concentration of stem cells delivered back to the patient offers an environment conducive to tissue regeneration.
The five-year agreement provides Celling with an initial 2 year period of exclusive distribution rights in the U.S. and non-exclusive distribution rights throughout the rest of the world, excluding Central and South America, Russia and certain Eastern European countries. ThermoGenesis will establish distributor relationships in those geographies.
ThermoGenesis received CE-Mark for the MXP, enabling the device to be marketed in the European Community and authorization from the FDA to begin marketing the MXP in the U.S., in June and July 2008, respectively.